Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis

Published:2022-09-14 Issue:1 Volume:7 Page:93-110
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Javanbakht Mehdi,Fishman Jesse,Moloney Eoin,Rydqvist Peter,Ansaripour Amir^ORCID

Funder

Madrigal Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-022-00370-2.pdf

Reference56 articles.

1. Stanfordhealthcare.org. 2021. Nonalcoholic Steatohepatitis (NASH). [online] https://stanfordhealthcare.org/medical-conditions/liver-kidneys-and-urinary-system/nonalcoholic-steatohepatitis-nash.html. Accessed 22 Feb 2022.

2. nhs.uk. 2022. Non-alcoholic fatty liver disease (NAFLD). [online]. https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/. Accessed 22 Feb 2022.

3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54.

4. Cks.nice.org.uk. 2021. Prevalence | Background information | Non-alcoholic fatty liver disease (NAFLD) | CKS | NICE. [online] https://cks.nice.org.uk/topics/non-alcoholic-fatty-liver-disease-nafld/background-information/prevalence/. Accessed 22 Feb 2022.

5. Garg K, Reinicke T, Garg SK. NAFLD and NASH and Diabetes. Diabetes Technology & Therapeutics. 2021;S-198-S-205. https://doi.org/10.1089/dia.2021.2515.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019;Metabolism;2024-09

2. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis);Journal of Medical Economics;2024-08-22

3. Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review;Journal of Clinical Medicine;2024-07-02

4. Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH);Annals of Pharmacotherapy;2024-06-17

5. Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease;Journal of Market Access & Health Policy;2024-04-02